MENSINGDERMAresearch GmbH — Clinical Trial Site

10 Registered trials

1 Currently recruiting

Organisation

MENSINGDERMAresearch GmbH

Location

Hamburg, Germany

Identifier

ORG-100044052

Address

Heegbarg 4, Poppenbüttel, 22391, Germany

Departments

"Dermatologisches Ambulatorium Hamburg-Alstertal"
2158
Dermatologisches Ambulatorium
Dermatology
MENSINGDERMA Research
MENSINGDERMA research GmbH
N/A
NA
Private practice

Clinical trials at this site (10)

Search interface

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the E… Recruiting

2023-505121-14-00 Moderate to Severe Plaque Psoriasis 5 2024-01-18
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co… Ended

2022-502161-19-00 Chronic Spontaneous Urticaria 5 2024-03-12
Long-term study to assess the safety and efficacy of Nemolizumab in subjects with Atopic Dermatitis Ended

2024-514404-13-00 Atopic Dermatitis 5 2020-10-01
A Phase 2, Dose-Ranging Study of LY4100511 (DC-853) in Adult Participants with Moderate-to-Severe Plaque Psoriasis Ended

2024-512207-39-00 Plaque Psoriasis 4 2025-01-30
Long-Term Extension Study (AtDvance) to Evaluate the Safety and Efficacy of GSK1070806 in Participants with Moderate to Severe Atopic Dermat… Ended

2023-508474-29-00 Dermatitis, Atopic 4 2024-10-30
A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding study to evaluate the Efficacy, Safety, Pharmacokinet… Ended

2023-505414-15-00 Dermatitis, Atopic 4 2024-04-10
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Ended

2022-503062-72-00 Chronic Spontaneous Urticaria 4 2023-11-23
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11
An efficacy and safety study of HRO350 in patients with mild-to-moderate psoriasis (the ‘HeROPA’ study) Ended

2022-501850-12-00 Psoriasis 4 2023-03-15
Moisturiser effect on atopic dermatitis relapse prevention in children Ended

2022-501184-41-00 atopic dermatitis/eczema 6 2023-02-13